Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Fang FangJun LuXu SangYan-Fang TaoJian-Wei WangZi-Mu ZhangYong-Ping ZhangXiao-Lu LiYi XieShui-Yan WuXin-Ran ChuGen LiDi WuYan-Ling ChenJuan-Juan YuSi-Qi JiaChen-Xi FengYuan-Yuan TianZhi-Heng LiJing LingShao-Yan HuJian PanPublished in: Journal of experimental & clinical cancer research : CR (2022)
In summary, we identified 200 common super-enhancer-associated genes in AML samples, and a series of those genes are cancer genes. We also found GNE-987 treatment downregulates the expression of super-enhancer-associated genes in AML cells, including the expression of LYL1. Further functional analysis indicated that LYL1 is required for AML cell growth and survival. These findings promote understanding of AML pathophysiology and elucidated an important role of LYL1 in AML progression.
Keyphrases
- acute myeloid leukemia
- genome wide
- genome wide identification
- binding protein
- allogeneic hematopoietic stem cell transplantation
- transcription factor
- poor prognosis
- papillary thyroid
- bioinformatics analysis
- dna methylation
- genome wide analysis
- induced apoptosis
- squamous cell
- oxidative stress
- cell proliferation
- acute lymphoblastic leukemia
- single cell
- signaling pathway
- endoplasmic reticulum stress
- smoking cessation